Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefield.
Joseph W
JW
Kim
Marijo
M
Bilusic
Elizabeth R
ER
Plimack
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy; D000074324:Ipilimumab; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy*; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology / Q000628:therapy*; D014781:Viscera / Q000473:pathology
D000911:Antibodies, Monoclonal; D000074324:Ipilimumab